Paul Marik’s Metabolic Approach to Cancer

Editorial Note — Freedom of Research and the Right to Be Heard. This page documents the research, writings, and claims of Dr. Paul E. Marik, the critical-care physician and former chief of pulmonary and critical care medicine at Eastern Virginia Medical School, known for his work on vitamin C in sepsis and on repurposed drugs, in the spirit of open scientific inquiry. The First Amendment’s protection of speech, and the long American tradition of medical dissent that runs from Semmelweis to Barry Marshall to Linus Pauling, exists precisely so that minority and unpopular research can be examined on its merits rather than silenced by institutional consensus. We present his facts and claims as he stated them, attributed to him, drawn from his papers and books. Readers are presumed to be intelligent adults capable of weighing evidence, consulting their own physicians, and making informed decisions about their own bodies. This page is provided for educational and historical-record purposes; it is not medical advice and does not endorse self-treatment. Censorship of a researcher is not refutation of the research. — MyHealthcare.com

Paul Ellis Marik is a South African-trained critical-care physician who worked in Canada and the United States, led the pulmonary and critical care division at Eastern Virginia Medical School, and in 2023 wrote Cancer Care: The Role of Repurposed Drugs and Metabolic Interventions in Treating Cancer, published free of charge by the Front Line COVID-19 Critical Care Alliance, now the Independent Medical Alliance (IMA).

This page sets out the metabolic half of that book as he states it: his view, built on the work of Otto Warburg and Thomas Seyfried, that cancer is mainly a disease of disordered energy production in the cell’s mitochondria; his reasoning about glucose as the tumour’s fuel; and the diet, fasting and lifestyle measures he places at the centre of treatment — calorie restriction, a ketogenic and “real food” low-carbohydrate diet, intermittent fasting, insulin resistance, exercise, sleep and sunshine. It also covers his 2023 review in the journal Nutrients, written with Matthew Halma and Jack Tuszynski, and then describes what later systematic reviews of ketogenic diets in cancer have found. His ranked list of repurposed drugs has its own page, Cancer Care: Paul Marik’s Book on Repurposed Drugs.

Cancer as a Metabolic Disease: The Theory He Builds On
Otto Warburg and the Warburg Effect
The Evidence He Cites for the Mitochondrial View
Glucose, Glutamine and the Aim to Starve the Cancer Cell
Calorie Restriction as the Central Intervention
The Ketogenic Diet and Real-Food Low-Carbohydrate Eating
Intermittent Fasting and Autophagy
Insulin Resistance, Sugar and Growth Signals
Weight Loss and Cancer Cachexia
Exercise, Sleep, Stress and Sunshine
The 2023 Nutrients Review and Later Research
Key Research Papers
Connections
Featured Videos

1. Cancer as a Metabolic Disease: The Theory He Builds On

The standard textbook account treats cancer as a disease of the genes: mutations accumulate in a cell’s DNA until it escapes the controls on growth. In Chapter 2 of Cancer Care, Marik sets out a different starting point. He cites the biologist Thomas Seyfried of Boston College, whose argument he summarises as the view “that cancer is primarily a metabolic rather than a genetic disease”. In this account cancer is a disorder of the mitochondria — the small structures inside each cell that burn fuel with oxygen to make energy — and, in Marik’s words, “the genomic abnormalities are likely secondary to disordered energy production”.

Seyfried’s own 2014 review in Carcinogenesis, one of the papers this line of thinking rests on, puts it this way in its summary: cancer is “primarily a metabolic disease involving disturbances in energy production through respiration and fermentation”, and the genomic instability and other recognised hallmarks of cancer are “downstream epiphenomena” of that first disturbance. The review links the disturbance to abnormalities in the structure and function of mitochondria.

Marik does not present the two views as mutually exclusive. He adds that “a very complex and bi-directional relationship exists between genetic instability and mitochondrial dysfunction” — damaged genes can harm mitochondria, and damaged mitochondria can harm genes. What follows from the metabolic view, for him, is a practical consequence: if the cancer cell depends on a faulty way of making energy, then the fuel supply itself becomes a target.

Back to Table of Contents

2. Otto Warburg and the Warburg Effect

Marik traces the metabolic idea to the German physiologist Otto Warburg, who received the Nobel Prize in Physiology or Medicine in 1931 for his work on the respiratory enzyme. In the 1920s Warburg observed that tumour cells take up large amounts of glucose and break much of it down by fermentation into lactic acid, even when enough oxygen is present for normal respiration. This pattern is now called the Warburg effect.

Warburg set out his explanation in a 1956 paper in Science, “On the origin of cancer cells”: he proposed that cancer begins with an irreversible injury to cellular respiration, after which the cell survives by switching to fermentation. Marik’s own one-line summary of what this means for a patient is: “In simple terms, this means cancer feeds on glucose.”

His 2023 review with Halma and Tuszynski states the same starting point in the language of the journal: “The Warburg hypothesis states that cancer cells have an altered cell metabolism towards anaerobic glycolysis” — that is, toward breaking down sugar without using oxygen. The rest of his metabolic programme follows from this sentence.

Back to Table of Contents

3. The Evidence He Cites for the Mitochondrial View

In Chapter 2 Marik lists the laboratory experiments that Seyfried and others use to argue that the mitochondria, not the nucleus, carry the decisive fault. They are all cell and animal experiments, not studies in patients:

Cybrid experiments. A “cybrid” (cytoplasmic hybrid) cell is made by fusing the nucleus of one cell with the cytoplasm — and so the mitochondria — of another. Marik reports experiments in which normal cytoplasm suppressed the ability of a tumour cell’s nucleus to form tumours.
Mitochondrial transfer. Experiments in which healthy mitochondria were moved into cancer cells, reported as changing the cells’ behaviour.
Nuclear transfer. Experiments in which the nucleus of a cancer cell, placed into normal cytoplasm, went on to form normal tissue.

Marik reads these results as showing that a cancer cell’s nucleus can behave normally when it sits in healthy cytoplasm, which he takes as support for the view that the energy-producing machinery is where cancer begins. These are experimental findings in cells and animals; they have not been tested as treatments in people.

Back to Table of Contents

4. Glucose, Glutamine and the Aim to Starve the Cancer Cell

Chapter 4 of Cancer Care, “The Metabolic Approach to Treating Cancer”, states the goal plainly: metabolic treatment aims to “starve the cancer cell” by acting on the pathways it uses to make energy. The 2023 review makes the same point: given the metabolic reprogramming of cancer cells, “it is possible to target cancers metabolically by depriving them of glucose.”

The reasoning comes from Seyfried’s papers, which Marik cites. They name two main fuels that tumour cells can ferment — glucose and the amino acid glutamine — and contrast them with ketone bodies, the fuel the liver makes from fat when carbohydrate is scarce:

Seyfried’s 2014 review proposes that cancer growth “can be managed following a whole body transition from fermentable metabolites, primarily glucose and glutamine, to respiratory metabolites, primarily ketone bodies.”
His 2012 review on brain cancer argues that “as long as brain tumor cells have access to glucose and glutamine, the disease will progress”, and describes a calorie-restricted ketogenic diet as targeting glucose and possibly glutamine. Its anti-tumour findings come from mice with brain tumours, together with human case reports.
His 2020 review on breast cancer calls glucose and glutamine “the prime fermentable fuels” and suggests ketogenic metabolic therapy would work best “together with glutamine targeting”.

The logic, as Marik presents it, is that healthy cells with working mitochondria can run on ketone bodies and fat, while cancer cells with damaged mitochondria cannot use them as well. Lowering glucose and raising ketones would then, in theory, put the tumour at a disadvantage while sparing normal tissue. Glucose cannot be removed from the blood entirely — the body makes its own from protein and other sources — so the approach aims to lower and steady blood glucose rather than eliminate it.

Back to Table of Contents

5. Calorie Restriction as the Central Intervention

Marik names one measure above all the others. In Chapter 4 he writes: “The most important and central approach to the metabolic treatment of cancers is dietary calorie (glucose) restriction”, to which repurposed drugs and nutritional supplements are added. The parenthesis matters: in his usage, cutting calories and cutting the glucose supply are two sides of the same measure.

He is careful about expectations. “It is important to emphasize that there is no single ‘magic bullet’”, he writes. He describes the metabolic approach as adjunctive — used alongside conventional cancer treatment such as surgery, chemotherapy and radiotherapy, not instead of it — and states his expectation that it may allow lower doses of chemotherapy to be used.

The book’s disclaimer frames the whole monograph the same way: it is “not intended as a stand-alone guide to treating cancer”, and he presents its contents for use “primarily as adjunctive therapy in addition to the treatment provided by an oncologist”. In his preface he adds: “I want to be clear that I am not suggesting I have found a cure for cancer.”

Calorie restriction has a long research history in animals. A 2014 systematic review in PLoS One gathered 59 animal studies of dietary restriction and cancer; about 90.9% of the calorie-restriction studies reported an anti-cancer effect, with a pooled odds ratio for tumour incidence of 0.20 against control animals across 21 studies. These are results in laboratory animals. The site’s Caloric Restriction page covers the wider research.

Back to Table of Contents

6. The Ketogenic Diet and Real-Food Low-Carbohydrate Eating

To put calorie and glucose restriction into practice, Chapter 4 describes two eating patterns:

A ketogenic diet — very low in carbohydrate, moderate in protein and high in fat, so that the body shifts to burning fat and making ketone bodies. Marik pairs it with calorie restriction, following Seyfried’s “restricted ketogenic diet”. The site’s Ketogenic Diet page explains the diet itself.
“Real Food: The Banting Diet” — his section heading for a low-carbohydrate diet built from whole, unprocessed foods. The name goes back to William Banting, a nineteenth-century London undertaker whose pamphlet on cutting starch and sugar became one of the first popular low-carbohydrate diets.

Both patterns are low in carbohydrate and neither is a low-fat diet. In Chapter 5, “Metabolic and Lifestyle Interventions”, he links the diet to measurement: he describes using a continuous glucose monitor — a small sensor worn on the skin that reads blood glucose through the day — to manage glucose alongside the ketogenic diet.

Seyfried’s group has since proposed a formal research framework. A 2024 paper in BMC Medicine by Duraj, Seyfried and more than forty co-authors sets out a consensus protocol for “ketogenic metabolic therapy” in glioblastoma, the most aggressive brain tumour in adults. It combines ketogenic diets, calorie restriction and fasting with drugs aimed at glucose and glutamine metabolism, and proposes the glucose-ketone index — the ratio of blood glucose to blood ketones — as a standard measure of whether a patient is actually in therapeutic ketosis. The paper is a proposal for how future studies should be run, not a trial result.

Back to Table of Contents

7. Intermittent Fasting and Autophagy

Chapter 4 also covers intermittent fasting — eating within a limited window, or going without food for set periods — and links it to autophagy, the cell’s own recycling process, in which worn-out proteins and damaged mitochondria are broken down and reused. In Marik’s account, fasting works with the diet toward the same goal of lowering the glucose supply.

The animal evidence for fasting is less consistent than for calorie restriction. The same 2014 PLoS One review of animal studies found that eight of nine ketogenic-diet studies reported an anti-cancer effect, but 37.5% of the intermittent-fasting studies concluded that fasting was not significantly preventive against cancer. Its authors wrote that calorie restriction and the ketogenic diet were effective against cancer in animal experiments “while the role of intermittent fasting is doubtful and still needs exploration.” The site’s Fasting page covers intermittent and extended fasting in more detail.

Back to Table of Contents

8. Insulin Resistance, Sugar and Growth Signals

Marik gives insulin a central place. In Chapter 4 he writes that insulin resistance — the state in which the body’s cells respond poorly to insulin, so the pancreas makes more of it and blood levels stay high — “plays a major role in the initiation and propagation of cancer”. High insulin acts as a growth signal, and in his view it helps both to start cancers and to keep them growing.

Several threads follow from this in the book:

Sugar and fructose. He describes sugar-sweetened drinks and fructose as cancer risks.
Laron syndrome. He cites Laron syndrome, a rare inherited condition in which the body cannot respond to growth hormone and so makes very little insulin-like growth factor 1 (IGF-1). People with the condition have a low rate of cancer, which he takes as evidence for the role of growth signalling through insulin-like growth factor 1.
Insulin potentiation therapy. He includes a section on insulin potentiation therapy — giving insulin together with low-dose chemotherapy — under a heading that ends in a question mark, marking it as an open question rather than a recommendation.

This is also where the metabolic programme meets the drug programme. Metformin, a diabetes drug that lowers blood glucose and insulin, is in the first tier of his ranked list of repurposed drugs; the evidence he cites for it is covered on the Cancer Care page.

Back to Table of Contents

9. Weight Loss and Cancer Cachexia

Restricting calories in a person who has cancer raises an obvious safety question. Many people with advanced cancer develop cachexia — a wasting syndrome of weight loss and loss of muscle that does not fully reverse with ordinary feeding and that is linked to weaker tolerance of treatment and shorter survival. Marik’s Chapter 4 includes a section on the management of cancer cachexia alongside the diet sections, treating it as a problem the metabolic approach has to deal with.

The clinical trials point the same way. A 2022 meta-analysis in Nutrition and Cancer pooled eight controlled trials of ketogenic diets in adults with cancer. The diet significantly reduced body weight, by about 4 kilograms on average (weighted mean difference −3.99 kg, from seven trials); in three trials in women with breast cancer the reduction was about 3.3 kilograms. The authors concluded that ketogenic diets “might result to a weight loss in adults with cancer”. For a person who is overweight this may be a goal; for a person who is already losing weight and muscle to cancer, the same loss is a hazard.

A strict ketogenic diet also alters the dose needs of some medicines. People taking insulin or sulfonylurea drugs for diabetes face a risk of low blood glucose when carbohydrate intake falls sharply, and people taking a class of diabetes drugs called sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) face a risk of ketoacidosis, a dangerous build-up of acid in the blood, on very low-carbohydrate diets.

Back to Table of Contents

10. Exercise, Sleep, Stress and Sunshine

Chapter 5 of Cancer Care, “Metabolic and Lifestyle Interventions”, widens the metabolic programme beyond food. Marik describes:

Glucose management with a continuous glucose monitor and the ketogenic diet, as above.
Exercise — both aerobic exercise and resistance (strength) training. Working muscle takes up glucose from the blood and improves the body’s response to insulin, which ties exercise back to his central theme.
Stress reduction and sleep as part of the same programme.
Comprehensive lifestyle change — the combination of diet, activity and rest rather than any one measure alone.
Sunshine, including a section titled “Sunshine and Skin Cancer”. Vitamin D, which the skin makes in sunlight, is the first agent on his ranked list of repurposed drugs and supplements.

He returned to the same themes in later guides written for the Independent Medical Alliance, including “Dietary Interventions in Cancer” (September 2025) and “The Metabolic Trap” (March 2026). On his own Substack, whose subtitle is “Effective Treatments using Diet, Repurposed Drugs and Nutraceuticals”, a March 2026 post frames the question as “Can we modify disease by modifying metabolism?” and adds: “The goal is not magical thinking, but mechanistic reasoning grounded in physiology.”

Back to Table of Contents

11. The 2023 Nutrients Review and Later Research

Marik’s peer-reviewed statement of the metabolic approach is a 2023 review in Nutrients, “Cancer Metabolism as a Therapeutic Target and Review of Interventions”, written with the physicist Matthew Halma and the biophysicist Jack Tuszynski. Its summary opens: “Cancer is amenable to low-cost treatments, given that it has a significant metabolic component, which can be affected through diet and lifestyle change at minimal cost.” The first half covers the Warburg hypothesis and the case for depriving tumours of glucose; the second half reviews nutritional supplements and repurposed drugs and the evidence for each. It is a narrative review — a summary of published studies chosen by the authors — not a new trial.

Later systematic reviews have looked at ketogenic diets in cancer directly. Described neutrally, by type of evidence:

In animals. A 2021 meta-analysis in Frontiers in Nutrition pooled 17 animal studies (38 in its review). The ketogenic diet prolonged survival time and reduced tumour weight and tumour volume, with the clearest survival effect at a 4:1 ratio of fat to protein plus carbohydrate. The authors wrote that the pre-clinical evidence pointed toward an overall anti-tumour effect “in animals studies currently available with limited tumor types”.
In people, randomised trials. A 2021 meta-analysis in Nutrients found six randomised controlled trials comparing a low-carbohydrate ketogenic diet with a non-ketogenic diet in people with cancer. It found no significant difference in cholesterol, body weight, fasting glucose or insulin. Three outcomes favoured the ketogenic diet: the tumour marker prostate-specific antigen, achievement of ketosis, and patient satisfaction. The authors concluded that “there was inadequate evidence to support the beneficial effects” of the diet on cancer treatment and that larger trials are needed.
Body weight. The 2022 Nutrition and Cancer meta-analysis of eight controlled trials, described in section 9, found an average weight loss of about 4 kilograms.
Brain cancer. Seyfried’s 2015 paper in Cancer Letters proposes metabolic therapy as an alternative to the standard of care for glioblastoma, and the 2024 BMC Medicine framework sets out how trials of ketogenic metabolic therapy in glioblastoma could be designed and measured.

Taken together, the animal studies largely report anti-tumour effects, while the randomised trials in people so far are few and small, and have measured blood markers, weight and ketosis rather than survival. Marik’s position, as stated in his book, is that the metabolic approach is a foundation for treatment used alongside conventional care.

Back to Table of Contents

Key Research Papers

Halma MTJ, Tuszynski JA, Marik PE. Cancer Metabolism as a Therapeutic Target and Review of Interventions. Nutrients. 2023;15(19):4245. — PubMed PMID: 37836529
Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-14. — PubMed PMID: 13298683
Seyfried TN, Flores RE, Poff AM, D’Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. 2014;35(3):515-27. — PubMed PMID: 24343361
Seyfried TN, Flores R, Poff AM, D’Agostino DP, Mukherjee P. Metabolic therapy: a new paradigm for managing malignant brain cancer. Cancer Lett. 2015;356(2 Pt A):289-300. — PubMed PMID: 25069036
Seyfried TN, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P. Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer? Epilepsy Res. 2012;100(3):310-26. — PubMed PMID: 21885251
Seyfried TN, Mukherjee P, Iyikesici MS, Slocum A, Kalamian M, Spinosa JP, et al. Consideration of Ketogenic Metabolic Therapy as a Complementary or Alternative Approach for Managing Breast Cancer. Front Nutr. 2020;7:21. — PubMed PMID: 32219096
Duraj T, Kalamian M, Zuccoli G, Maroon JC, D’Agostino DP, Scheck AC, et al. Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma. BMC Med. 2024;22(1):578. — PubMed PMID: 39639257
Yang YF, Mattamel PB, Joseph T, Huang J, Chen Q, Akinwunmi BO, et al. Efficacy of Low-Carbohydrate Ketogenic Diet as an Adjuvant Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2021;13(5):1388. — PubMed PMID: 33918992
Li J, Zhang H, Dai Z. Cancer Treatment With the Ketogenic Diet: A Systematic Review and Meta-analysis of Animal Studies. Front Nutr. 2021;8:594408. — PubMed PMID: 34179051
Taftian M, Beigrezaei S, Arabi V, Salehi-Abargouei A. The Effect of Ketogenic Diet on Weight Loss in Adult Patients with Cancer: A Systematic Review and Meta-Analysis of Controlled Clinical Trials. Nutr Cancer. 2022;74(4):1222-1234. — PubMed PMID: 35129013
Lv M, Zhu X, Wang H, Wang F, Guan W. Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis. PLoS One. 2014;9(12):e115147. — PubMed PMID: 25502434

Paul Marik’s Metabolic Approach to Cancer

Table of Contents

1. Cancer as a Metabolic Disease: The Theory He Builds On

2. Otto Warburg and the Warburg Effect

3. The Evidence He Cites for the Mitochondrial View

4. Glucose, Glutamine and the Aim to Starve the Cancer Cell

5. Calorie Restriction as the Central Intervention

6. The Ketogenic Diet and Real-Food Low-Carbohydrate Eating

7. Intermittent Fasting and Autophagy

8. Insulin Resistance, Sugar and Growth Signals

9. Weight Loss and Cancer Cachexia

10. Exercise, Sleep, Stress and Sunshine

11. The 2023 Nutrients Review and Later Research

Key Research Papers

PubMed Topic Searches

Further Reading

Connections

Featured Videos